### Financial Highlights
- Net Income: -$371,332, reflecting a 29.20% decrease year-over-year and a 2.32% decline from the previous quarter.
- Research and Development Expenses: $226,088, emphasizing the company's commitment to innovation despite financial losses.
- General and Administrative Expenses: $145,244, underscoring significant overhead costs.
- Cash Position: Ending cash at $297, a stark warning signal for operational sustainability.
- EPS: -$0.0028, with a slight drop indicating the continuous loss per share expected in the biotechnology industry's high-risk environment.
### Ratios Analysis
- Current Ratio: 0.00774, indicating an acute liquidity crisis with current liabilities overwhelming current assets.
- Return on Equity: -372.45%, pointing to severe losses against shareholder equity, which remains negative, indicating the need for capital infusion or restructuring.